{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-23-000984","form_type":"8-K","ticker":"ARCT","cik":"0001768224","company_name":"Arcturus Therapeutics Holdings Inc.","filed_at":"2023-07-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.165713+00:00","generated_at":"2026-06-13T08:18:25.389016+00:00","sec_items":["7.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"medium","headline":"Arcturus announces medRxiv preprint of Phase 3 data for ARCT-154 booster vs. Comirnaty","bullets":["Preprint on medRxiv reports interim Phase 3 results from Japan comparing ARCT-154 booster to Comirnaty.","Study conducted by Meiji Seika Pharma, Arcturus' collaborator, evaluating safety and immunogenicity.","Meiji has a distribution agreement with CSL Seqirus for ARCT-154 in Japan, previously announced on April 11, 2023.","The article is a preprint and has not yet been peer-reviewed; no specific results are provided in the filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-23-000984","json":"https://secwatch.observer/filing/0001193805-23-000984.json","markdown":"https://secwatch.observer/filing/0001193805-23-000984.md","text":"https://secwatch.observer/filing/0001193805-23-000984.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768224/000119380523000984/0001193805-23-000984-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768224/000119380523000984/e618777_8k-arct.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T08:18:25.389016+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}